About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Photo credit: Borja Ruiz Rodriguez/MSF

Time for $5

The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.

Our campaigns

Events |

11 January 2007

No Time to Wait - TB symposium NY - agenda

TUBERCULOSIS

Download

A Médecins Sans Frontières/Doctors Without Borders Symposium supported by Howard P. Milstein and Weill Cornell Medical College’s Abby and Howard P. Milstein Program in Chemical Biology.